Last Updated： Aggregation Period:Dec 17, 2025～Jan 13, 2026
This ranking is based on the number of page views on our site.
Last Updated： Aggregation Period:Dec 17, 2025～Jan 13, 2026
This ranking is based on the number of page views on our site.
Last Updated： Aggregation Period:Dec 17, 2025～Jan 13, 2026
This ranking is based on the number of page views on our site.
1～15 item / All 599 items
Comprehensive workflow solution for Agilent's oligonucleotides.
Agilent supports a comprehensive workflow that incorporates optimized instruments, software, columns, and consumables for oligonucleotide analysis. Additionally, Agilent also supports GMP manufacturing of commercial quantities of oligonucleotides in later stages.
Five manufacturing buildings, a quality control building, an office building, and a wastewater treatment facility are all included! It has a manufacturing license for pharmaceuticals.
Tateyama Kasei Co., Ltd.'s Kyushu factory is located in Tagawa City, which is situated in the central part of Fukuoka Prefecture. It began operations in 1972 and is equipped with five manufacturing buildings, a quality control building, an office building, and wastewater treatment facilities. Notable equipment includes an indirect cooling type ultra-low temperature reaction device and a filtration dryer. The factory holds a manufacturing license for pharmaceuticals and has two lines of 6000L active pharmaceutical ingredient purification equipment, making it suitable for the production of relatively large quantities of stable active pharmaceutical ingredients. [Features] - Possesses an indirect cooling type ultra-low temperature reaction device and a filtration dryer - Holds a manufacturing license for pharmaceuticals - Well-suited for the production of relatively large quantities of stable active pharmaceutical ingredients *For more details, please refer to the PDF document or feel free to contact us.
BRAFV600E mutation cancer treatment agent
The BRAFV600E mutation is observed in multiple cancer types and is associated with a poor prognosis compared to other molecular subtypes. In the treatment of BRAF-mutant colorectal cancer patients, targeted therapies have been developed and clinically introduced in 2020, including combination therapies of BRAF inhibitors with anti-EGFR antibody drugs, as well as a three-drug combination therapy of BRAF inhibitors, MEK inhibitors, and anti-EGFR antibody drugs. However, BRAF-mutant colorectal cancer still has a poor prognosis, and further effective treatment strategies are needed. Therefore, this invention proposes that retinoid receptor (particularly RARα or RXRα) agonists can enhance treatment effects or overcome acquired resistance in combination therapies of BRAF inhibitors with anti-EGFR antibody drugs or BRAF inhibitors, MEK inhibitors, and anti-EGFR antibody drugs, potentially serving as an effective treatment strategy for cancers with BRAFV600E, particularly colorectal cancer.
Components found in mammalian milk suppress the progression of kidney disorders, sarcopenia, and anemia.
Chronic kidney disease currently affects about 1 in 8 adults and is said to be a new national disease in Japan. The treatment aims to slow the progression of symptoms, particularly to prevent the progression to end-stage renal failure and the onset of cardiovascular diseases. CKD also has complications such as bone disorders, muscle atrophy (sarcopenia), and anemia, and there are no effective treatments available. This invention relates to the effects of a protein called lactoferrin (Lf) on the progression and complications of chronic kidney disease (CKD). It was found that the administration of Lf has both preventive effects before the onset of CKD and therapeutic effects after its onset in adenine-induced renal failure model mice (Reference 1). Specifically, the effects of Lf in suppressing sarcopenia (reduction of muscle cross-sectional area, decrease in the accumulation of uremic toxins in muscles), anemia, renal atrophy, tubular interstitial damage, decline in kidney function, and inflammation and fibrosis in the kidneys were confirmed.
Drug repositioning of Lubiprostone Exploratory P2 is over!
Toxin adsorbents such as SGLT2 inhibitors and cremedin have been used as pharmacotherapy for kidney disease. Lubiprostone, which is also used as a constipation drug, was shown to be effective as a treatment for chronic kidney disease (CKD). Lubiprostone was also found to suppress the decline in renal function. In an investigator-initiated clinical trial, the inventors conducted an exploratory study to investigate the efficacy and safety of 8 μg/day and 16 μg/day of lubiprostone in reducing renal function in patients with chronic kidney disease, using a placebo control. (The results can be disclosed under individual contracts.)
Over 1000 times affinity to bind with RNA virus (vs. DPQ)! Promising diagnostic and inhibitory drug!
Introduction Influenza prevails broadly every season. Current diagnostic drugs can not be performed until the virus increases quite a lot (ca. 12~24h after infection, symptoms may appear), and if not so, both sensitivity and accuracy of the test will be doubtful. To prevent on-going severe symptoms, new diagnostic tech for influenza at earlier stage becomes so demanded. This invention provides a conjugate of peptide nucleic acid sequence (PNA) and a small molecule, targeting the commonly identical RNA hairpin promoter region of eight kinds of influenza A virus. Effect & Application The conjugate (tFIT-DPQ probe) is composed of two parts: tFIT unit for recognition of virus RNA’s nucleotides and DPQ* unit for UAA internal loop binding. In tFIT unit, a fluorescent ligand is inserted so as to be capable to emit signals when intercalating to RNA duplex (Fig. 1). The conjugate shows an over 1000 times greater binding affinity than DPQ molecule only (Fig. 2). By simply mixing the virus RNA contained sample and the conjugate together, test result will be obtained within a short time (ca. 2~3 min) and 1nM virus RNA (ca. 1010 copies) can be detected. Moreover, the virus inhibition effect by the conjugate in micromolar range was confirmed (Fig. 3). tFIT-DPQ probe is expected to be applied as diagnostic and inhibitory drugs, as well as a screening tool for influenza drug candidates.
New drug discovery seeds for psychiatric disorders such as schizophrenia
Recent large-scale genomic and postmortem brain analyses have indicated that synaptic dysgenesis may be involved in the pathogenesis of schizophrenia, but the detailed mechanisms remain unclear. Drugs mainly blocking dopamine D2 receptors have been used for the treatment of schizophrenia, but they are mainly used for symptomatic treatment and have insufficient effects on negative symptoms and cognitive dysfunction. Therefore, it is desirable to develop new drugs based on new molecular mechanisms. The inventors have discovered that the decreased function of the PPARA gene, which encodes the nuclear receptor PPARα, is involved in the pathogenesis of schizophrenia [1]. Since PPARα is a transcription factor that can be activated by its ligand, they considered the possibility that activation of PPARA might lead to the improvement of schizophrenia, and found that fenofibrate, a PPARa agonist, is actually effective in improving synaptic function [2]. In this study, they found that pemafibrate, a PPARa agonist, helps to improve cognitive function at the same time as restoring spine density in mice. The invention could lead to the discovery of novel mechanisms for schizophrenia. Furthermore, since decreased spine density and cognitive decline are similar symptoms in other psychiatric disorders such as Alzheimer's, it could also be a therapeutic agent for these disorders.
We support consistent quality control from raw materials to active pharmaceutical ingredients, including method development and stability testing!
Otsuka Chemical Co., Ltd. offers pharmaceutical CDMO services. Utilizing organic synthesis technology cultivated over many years in pharmaceutical manufacturing, we provide a consistent service from special raw materials to intermediates and mid-sized active pharmaceutical ingredients. With over 60 years of experience in halogenation technology and our unique catalyst development technology, we respond to diverse needs. Please feel free to contact us when you need our services. 【Features】 ■ High pharmacological activity (OEB Category 4) with solid-phase synthesis / flow synthesis capabilities Newly established GMP-compliant multi-purpose plant ■ Consistent service from special raw materials to intermediates and mid-sized active pharmaceutical ingredients ■ Responding to diverse needs through halogenation technology and unique catalyst development technology *For more details, please refer to the PDF document or feel free to contact us.
Are you particular about the "freezing method" of pharmaceutical raw materials? It is possible to freeze and thaw raw materials more safely and securely while maintaining quality!
Of the biopharmaceutical active ingredients, 59.4% are transported in a frozen state. Therefore, the development of controllable and efficient freezing and thawing technologies is increasingly in demand. For example, in the development of COVID-19 vaccines, there has been a growing emphasis on storage and transportation methods, highlighting the necessity for these solutions. Recently, the combination of Allegro BioContainers and RoSS Technology has resulted in the development of an excellent active ingredient management solution through synergistic effects. It allows for the control of frozen active ingredients between the purification process and the formulation and filling processes, enabling stable and safe storage and transportation. Additionally, it prevents losses of active ingredients due to the breakage of frozen single-use packs, bringing the risk of loss close to 0%.
We will organize a total healthy happiness and comfortable environment.
Towa Pharmaceutical Co., Ltd. is a company that primarily manufactures patches, cooling sheets, and topical liquid agents. We prioritize quality assurance from the delivery of raw materials to manufacturing and shipping, and we have over 50 years of experience in the development and production of topical agents since our founding. 【Our Original Brands】 ■ Anti-itch and anti-inflammatory medication "Cocora EX" ■ Pain relief and anti-inflammatory agent "Koriafuta Series" ■ Cooling material for soft tissue therapy "Towa Sheet" *For more details, please download the PDF or feel free to contact us.
Introducing pH measurement reagents! The pH measurement range is from 6.0 to 7.6.
The "BTB Indicator (Bromothymol Blue Solution)" is an indicator for pH measurement. By adding this product at a ratio of 0.5 mL to 10 mL of the sample water in a transparent container (or colorimetric cell for measuring devices), pH can be measured within the range of 6.0 to 7.6. It is recommended to use a pH meter to compare the color of the colorimetric plate with the color of the sample water after adding the indicator for measuring the pH value. 【Features】 ■ Add this product at a ratio of 0.5 mL to 10 mL of the sample water ■ It is recommended to use a pH meter to compare the color of the colorimetric plate with the color of the sample water after adding the indicator for measuring the pH value *For more details, please refer to the PDF document or feel free to contact us.
Introduction of compounds expected to be developed as new NASH treatments.
At Renac Therapeutics, we handle "Pharmaceutical Pipeline NASH Therapeutics (Nucleic Acid Medicines)." Using our proprietary technology, Hetero Double-Stranded Nucleic Acid (HDO) technology, we have discovered compounds that inhibit the expression of the NASH-related gene IHH. These compounds are expected to improve the NAFLD activity score in NASH animal models by inhibiting IHH expression, paving the way for the development of a novel NASH therapeutic. [Features] - Effectively inhibits the expression of the NASH-related gene IHH. - Also suppresses the expression of fibrosis marker genes such as COL1A1, CTGF, and TIMP1, suggesting potential as a fibrosis treatment. *For more details, please refer to the PDF document or feel free to contact us.
Suitable for measuring chemical oxygen demand (COD) of various water qualities!
This test reagent is suitable for measuring the chemical oxygen demand (COD) of various water qualities, including surface water, groundwater, municipal wastewater, and industrial effluent. Please note that if the concentration of chloride ions in the sample is 1500 mg/L or higher, it may affect the measurement results, so please dilute the sample liquid with pure water before use. 【Features】 ■ Measurement Principle - Spectrophotometric method, dichromate method (CODcr) ■ Chloride Ion Interference - ≤2000 mg/L ■ Processing Time - 20 min @ 165℃ *For more details, please refer to the PDF document or feel free to contact us.
To further enhance gloss, color development, and strength! We propose suitable materials utilizing the technology of ceramic tile glazes.
"Glaze" is an essential product that enables the luster and diverse coloration of tiles, serving as a material to enhance strength. It is a type of glass that covers the surface of ceramics, such as pottery, essentially acting as a coating material for ceramics. It contains various components, which give it distinctive design and functional characteristics. At our company, we leverage this technology, developed over many years, to propose suitable products tailored to specific applications. [Examples of Applications] ■ Tiles with a glass-like luster ■ Tiles with metal crystals precipitated on the surface ■ Tiles finished with a matte surface that reflects light diffusely, etc. *For more details, please refer to the related links or feel free to contact us.
